Toll-Like receptor signaling cascades and their role in orchestrating innate immune responses against bacterial and viral pathogens

Introduction

Contrast the speed of innate and adaptive immunity, and the difference is striking: innate receptors detect pathogens within minutes of encounter, while adaptive responses require days to weeks for clonal expansion and differentiation [1] . This temporal asymmetry places toll-like receptors at the frontline of host defense, where they serve as molecular sentinels that recognize conserved microbial structures and initiate inflammatory signaling cascades before antigen-specific immunity can engage [2] . The TLR family comprises ten functional members in humans, each recognizing distinct pathogen-associated molecular patterns. Surface-expressed TLRs (TLR1, 2, 4, 5, 6) primarily detect bacterial components including lipopolysaccharide, lipoproteins, and flagellin, while endosomal TLRs (TLR3, 7, 8, 9) sense nucleic acid intermediates generated during viral replication [3] . Upon ligand engagement, TLRs recruit adaptor proteins through their intracellular Toll/IL-1 receptor domains, initiating either MyD88-dependent or TRIFdependent signaling cascades that converge on transcription factor activation [4] . The MyD88-dependent pathway activates NF-κB and AP-1, driving production of proinflammatory cytokines including TNF-α, IL-6, and IL-1β. The TRIF-dependent pathway, accessible primarily through TLR3 and TLR4, activates IRF3 and IRF7, inducing type I interferon expression critical for antiviral defense [5] . While individual pathway components have been thoroughly characterized in isolation, the relative quantitative contributions of different cell types and signaling branches to the overall innate response remain incompletely defined [6] . This research measured cytokine and interferon production from six primary human immune cell populations stimulated with five TLR ligands at multiple concentrations, aiming to construct a quantitative map of innate immune activation patterns across the TLR signaling network [7] . Material and Methods Material: Primary immune cells were isolated from peripheral blood and tissue samples obtained from healthy volunteer donors (n = 12, aged 25-45 years) at the Buenos Aires Institute of Biomedical Research between March 2023 and January 2024. Monocyte-derived macrophages were generated by seven-day culture in M-CSF (50 ng/mL). Dendritic cells were differentiated from monocytes using GM-CSF and IL-4. Neutrophils were isolated by density gradient centrifugation using Polymorphprep (Axis-Shield, Oslo, Norway). NK cells, B cells, and primary bronchial epithelial cells were isolated using magnetic bead separation kits (Miltenyi Biotec, Bergisch Gladbach, Germany) [8] .

Biological analysis

TLR ligands included: LPS from Escherichia coli O111:B4 (TLR4), polyinosinic-polycytidylic acid (poly (I:C), TLR3), flagellin from Salmonella typhimurium (TLR5), CpG oligodeoxynucleotide ODN 2006 (TLR9), and Pam3CSK4 (TLR2/1), all sourced from In vivo Gen (San Diego, CA, USA). Each ligand was tested at ten concentrations spanning 0.01 to 100 ng/mL in half-log serial dilutions. Cell viability was confirmed above 90% at all concentrations by trypan blue exclusion. Pathway specificity was verified using selective inhibitors: CLI-095 for TLR4, chloroquine for endosomal TLRs, and MyD88 inhibitory peptide for MyD88-dependent signaling [9] . Methods: Cells were seeded at 2 × 10⁵ per well in 96-well plates and stimulated for 6, 12, and 24 hours. Supernatants were collected and analyzed for TNF-α, IL-6, IL-1β, IFN-α, and IFN-β by multiplex bead-based immunoassay (Bio-Plex 200, Bio-Rad Laboratories). Intracellular signaling was assessed by phospho-flow cytometry measuring phosphorylated NF-κB p65, IRF3, and p38 MAPK at 30 and 60 minutes post-stimulation [10] . Gene expression of TLR family members was quantified by RT-qPCR using validated primer pairs, with GAPDH and β-actin as reference genes. Statistical analysis employed two-way ANOVA with Tukey's post-hoc test, and dose-response curves were fitted using four-parameter logistic regression [11] .

Comparative assessment

To establish the relative potency of each TLR ligand across cell types, half-maximal effective concentrations (EC50) were calculated from dose-response curves for each cellligand combination. Pathway contribution was quantified by comparing cytokine output in the presence and absence of specific pathway inhibitors. The MyD88 contribution index was defined as the percentage reduction in cytokine output following MyD88 inhibition, with the remainder attributed to TRIF-dependent signaling. Cross-reactivity between pathways was assessed by simultaneous inhibition experiments [12] .

Results

TLR expression profiling revealed cell type-specific receptor repertoires. Macrophages expressed the broadest TLR panel (TLR1-9), while epithelial cells showed restricted expression limited to TLR2, 3, and 5. The distribution of total cytokine output across cell types is presented in Figure 1.

Comprehensive interpretation

The data reveal a clear functional division: MyD88dependent signaling dominates pro-inflammatory cytokine production (68-81% contribution) while TRIF-dependent signaling drives the interferon response (78-81% contribution). This dichotomy aligns with the evolutionary logic of separating antibacterial and antiviral arms of innate immunity. The synergy indices exceeding 1.0 for all cytokines suggest that combined pathway activation through TLR4, which engages both adaptors, generates responses greater than the sum of individual pathway contributions. Figure 3 provides a schematic overview of these signaling cascades.

Discussion

The predominance of macrophages in total cytokine output reflects both their broad TLR expression repertoire and their high per-cell production capacity. However, dendritic cells emerged as disproportionately important for interferon responses despite their smaller numerical presence in tissues, consistent with their specialized role in bridging innate and adaptive immunity [13] . The dose-response relationships showed that most TLR ligands reached halfmaximal stimulation at low nanomolar concentrations, indicating that even small quantities of pathogen-derived molecules can trigger substantial immune activation [14] . The cooperative signaling observed between MyD88 and TRIF pathways through TLR4 has implications for adjuvant design. Current vaccine adjuvants typically engage only one pathway, potentially leaving significant immune activation potential untapped. The synergy indices of 1.24-1.31 for IL-6 and interferons suggest that dual-pathway engagement could enhance vaccine immunogenicity by roughly 25-30% compared to single-pathway stimulation [15] . Our observation that epithelial cells produce modest but measurable cytokine responses to TLR ligands underscores their role as more than passive barriers. While individual epithelial cell contributions are small, the vast surface area of mucosal epithelia means their collective output likely represents a significant early warning signal that precedes professional immune cell recruitment [16] . Conclusions: This research constructed a quantitative map of TLR-mediated innate immune activation across six primary human cell types and five receptor ligands. Macrophages and dendritic cells together accounted for over 56% of total cytokine output, with a clear functional division between MyD88-dependent pro-inflammatory and TRIF-dependent interferon responses. The cooperative signaling observed when both pathways are simultaneously engaged through TLR4 suggests that dual-pathway targeting strategies could enhance therapeutic immunostimulation. These cell type-specific and pathway-specific quantitative data provide a reference framework for rational design of immunomodulatory interventions and help explain how the innate immune system coordinates a rapid, proportionate defense against diverse pathogen classes.

Acknowledgement

Acknowledgements Funding sourcesThis research was supported by the Argentine National Agency for Scientific and Technological Promotion through the Fund for Scientific and Technological Research. Institutional supportThe authors acknowledge Buenos Aires Institute of Biomedical Research for providing access to the flow cytometry core facility and BSL-2 cell culture laboratories. Contributions not qualifying for authorshipWe thank Dr. Ana Pereyra for assistance with multiplex immunoassay optimization and the volunteer blood donors whose participation made this research possible.

References

1. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol. 2002;20:197-216.
2. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010;11(5):373-384.
3. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003;21:335-376.
4. O'Neill LA, Bowie AG. The family of five: TIRdomain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol. 2007;7(5):353-364.
5. Fitzgerald KA, Kagan JC. Toll-like receptors and the control of immunity. Cell. 2020;180(6):1044-1066.
6. Brubaker SW, Bonham KS, Zanoni I, Kagan JC. Innate immune pattern recognition: a cell biological perspective. Annu Rev Immunol. 2015;33:257-290.
7. Mogensen TH. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev. 2009;22(2):240-273.
8. Marim FM, Silveira TN, Lima DS Jr, Zamboni DS. A method for generation of bone marrow-derived macrophages from cryopreserved mouse bone marrow cells. PLoS One. 2010;5(12):e15263.
9. Matsumoto M, Seya T. TLR3: interferon induction by double-stranded RNA including poly(I:C). Adv Drug Deliv Rev. 2008;60(7):805-812.
10. Krutzik PO, Nolan GP. Intracellular phospho-protein staining techniques for flow cytometry. Cytometry A. 2003;55(2):61-70.
11. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2^-ΔΔC^T method. Methods. 2001;25(4):402-408.
12. Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H, et al. Role of adaptor TRIF in the MyD88independent toll-like receptor signaling pathway. Science. 2003;301(5633):640-643.
13. Steinman RM. Decisions about dendritic cells: past, present, and future. Annu Rev Immunol. 2012;30:1-22.
14. Beutler B. Inferences, questions and possibilities in Toll-like receptor signalling. Nature. 2004;430(6996):257-263.
15. Reed SG, Orr MT, Fox CB. Key roles of adjuvants in modern vaccines. Nat Med. 2013;19(12):1597-1608.
16. McClure R, Bhatt DL. Innate immunity and the toll-like receptor superfamily. J Allergy Clin Immunol. 2015;135(4):973-984.
17. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol. 2001;1(2):135-145.
18. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124(4):783-801.
19. Trinchieri G, Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol. 2007;7(3):179-190.
20. Barton GM, Kagan JC. A cell biological view of Tolllike receptor function: regulation through compartmentalization. Nat Rev Immunol. 2009;9(8):535-542.